The Third Booster Vaccination Dose Against COVID-19: Indications for Circulating SARS-CoV-2 Variants

Rahimi, Farid; Abadi, Amin Talebi Bezmin

doi:10.2217/fvl-2021-0240

Cited by 5 publications

(5 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a preliminary evaluation after a Comirnaty booster in Israel, recipients reported 80% local and 40% systemic reactions [ 17 ]. Furthermore, other reports described reactions as milder than previous injections, with increased local but decreased systemic reactions [ 18 ]. Although the rate of adverse events after heterologous booster with respect to the last dose received was higher than homologous vaccinations, considering that enrolled recipients had received four different initial vaccine courses (2-doses of Comirnaty, Spikevax, or Vaxzevria, 1-dose cycle of Janssen or for previous COVID-19 history), both boosting types showed acceptable side-event profiles.…”

Section: Discussionmentioning

confidence: 99%

A Cross-Sectional Study of Untoward Reactions Following Homologous and Heterologous COVID-19 Booster Immunizations in Recipients Seventeen Years of Age and Older

et al. 2022

View full text Add to dashboard Cite

A booster dose after primary COVID-19 vaccination series was considered crucial after the emergence of the B.1.617.2 (Delta) and B.1.1.529 (Omicron) variants. Active surveillance was used to investigate reporting of adverse events post-booster dose of either of the licensed mRNA Comirnaty (Pfizer/BioNTech) or Spikevax (Moderna) vaccines in adult (17 years and older) recipients in central Italy. Eligible participants were enrolled and interviewed via phone using a structured questionnaire. Primary outcomes related to the occurrence of adverse events post-booster were stratified by vaccine, and frequency of local/systemic, mild/moderate/severe events. Of a total of 622 participants interviewed, 554 (89.1%) reported at least one adverse event (88.2% and 92.9% after the Comirnaty or Spikevax vaccine, respectively): 63.4% were female, and 78.5% aged 17 to 64 years, regardless of vaccine. 87.7% and 68.2% of all recipients described at least one local or systemic reaction, respectively: 97.3, 38.6 and 4.7% reported mild, moderate, or severe events, respectively. The most frequent adverse reactions were pain, redness, or swelling at the injection site and fatigue, while malaise and fever significantly occurred after the Comirnaty, and vomiting after the Spikevax booster. Compared to the primary vaccination, lymphadenopathy was more common after the booster (p < 0.001), especially after Comirnaty vaccine. The study findings revealed no serious or unexpected adverse events, and are in agreement with data available on booster dose for both mRNA vaccines. The transient, mild to moderate, and common to very common side reactions reported should be used to reassure potential recipients of the lack of safety concerns.

show abstract

Section: Discussionmentioning

confidence: 99%

A Cross-Sectional Study of Untoward Reactions Following Homologous and Heterologous COVID-19 Booster Immunizations in Recipients Seventeen Years of Age and Older

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Still, some studies, e.g., [6] have shown no such correlations. Therefore, the implementation of an effective vaccine program against COVID-19 is essential for overcoming the pandemic [7][8][9]. Such a program can be implemented through collaboration between governments, scientific communities, and pharmaceutical manufacturers [10,11].…”

Section: Introductionmentioning

confidence: 99%

The public’s attitude to and acceptance of periodic doses of the COVID-19 vaccine: A survey from Jordan

et al. 2022

View full text Add to dashboard Cite

Aims This study surveyed people regarding their acceptance of periodic doses (i.e., annual boosters) of the COVID-19 vaccine. Moreover, factors that correlate with attitudes toward periodic COVID-19 vaccines were assessed and identified. Method The study employed a cross-sectional methodology. The study questionnaire was distributed using Google Forms. Data were collected during the last quarter of 2021, and 1,416 adults (18 years old and over) from Jordan responded. Acceptance of COVID-19 periodic vaccine doses was calculated as a percentage of the total number of study participants, and their attitudes were scored. A multiple regression model was used to determine the predictors of public attitudes toward the annual dose of COVID-19 vaccines. Results The acceptance rate for receiving periodic doses of the COVID-19 vaccine was low (19.3%). Additionally, 26% of participants were unsure about receiving additional doses of the vaccine. However, 54.7% had a negative attitude toward getting periodic doses. The mean score for attitudes toward periodic doses was 47.9 (range: 29–66). Among the identified factors leading to decisions not to receive periodic doses were side effects (49.1%), waiting for further clinical studies (38.8%), and perceived no risk of contracting COVID-19 (17.7%). Regression analysis showed that income, educational attainment, and following the news about COVID-19 were predictors of participants’ attitudes toward the periodic COVID-19 vaccine. Conclusion Acceptance of periodic doses of the COVID-19 vaccine in Jordan is low, and the public’s attitude is generally negative. Health programs and educational interventions are needed to promote vaccine acceptance and positive attitudes.

show abstract

“…To prevent vaccine breakthrough infections, fully vaccinated populations should still practice preventive measures. Furthermore, many recent studies have indicated that a vaccine booster dose could rapidly recall a SARS‐CoV‐2‐specific immune response, leading to a significant rebound in antibody levels, which promotes high effectiveness against circulating variants such as Delta to prevent breakthrough infection 20,45–48 . Therefore, universal booster vaccination could be a current strategy to prevent breakthrough infections from COVID‐19.…”

Section: Discussionmentioning

confidence: 99%

Genomic, immunological, and clinical analysis of COVID‐19 vaccine breakthrough infections in Beijing, China

Tian

Song

Zhang

et al. 2022

Journal of Medical Virology

View full text Add to dashboard Cite

As the coronavirus disease 2019 (COVID‐19) pandemic is still ongoing and severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) variants are circulating worldwide, an increasing number of breakthrough infections are being detected despite the good efficacy of COVID‐19 vaccines. Data on 88 COVID‐19 breakthrough cases (breakthrough infections group) and 41 unvaccinated cases (unvaccinated group) from June 1 to August 22, 2021, were extracted from a cloud database established at Beijing Ditan Hospital to evaluate the clinical, immunological, and genomic characteristics of COVID‐19 breakthrough infections. Among these 129 COVID‐19 cases, 33 whole genomes were successfully sequenced, of which 23 were Delta variants, including 15 from the breakthrough infections group. Asymptomatic and mild cases predominated in both groups, but two patients developed severe disease in the unvaccinated group. The median time of viral shedding in the breakthrough infections group was significantly lower than that in the unvaccinated group (p = 0.003). In the breakthrough infections group, the IgG titers showed a significantly increasing trend (p = 0.007), and the CD4 + T lymphocyte count was significantly elevated (p = 0.018). For people infected with the Delta variant in the two groups, no significant difference was observed in either the quantitative reverse‐transcription polymerase chain reaction results or viral shedding time. In conclusion, among vaccinated patients, the cases of COVID‐19 vaccine breakthrough infections were mainly asymptomatic and mild, IgG titers were significantly increased and rose rapidly, and the viral shedding time was shorter.

show abstract

The Third Booster Vaccination Dose Against COVID-19: Indications for Circulating SARS-CoV-2 Variants

Cited by 5 publications

References 19 publications

A Cross-Sectional Study of Untoward Reactions Following Homologous and Heterologous COVID-19 Booster Immunizations in Recipients Seventeen Years of Age and Older

A Cross-Sectional Study of Untoward Reactions Following Homologous and Heterologous COVID-19 Booster Immunizations in Recipients Seventeen Years of Age and Older

The public’s attitude to and acceptance of periodic doses of the COVID-19 vaccine: A survey from Jordan

Genomic, immunological, and clinical analysis of COVID‐19 vaccine breakthrough infections in Beijing, China

Contact Info

Product

Resources

About